ABSTRACT
introduction
Lateral epicondylitis is a common cause of lateral elbow pain, with a prevalence of 1% to 3% in the general population aged 45 to 54 years. 1, 2 It is considered a degenerative process (rather than an inflammatory process), characterised by angiofibroblastic degeneration or hyperplasia within the common extensor tendon, particularly affecting the extensor carpi radialis brevis. 3 Treatment can be conservative ('wait and see', activity modification, rest, bracing, physical therapy, non-steroidal anti-inflammatory drugs, and local injections) or surgical (open, percutaneous, or arthroscopic release of the extensor origin, debridement and denervation of the lateral epicondyle, and anconeus rotation). 4, 5 The most common treatment is local injection of corticosteroid combined with local anaesthetics. Autologous blood injection delivers blood borne cellular and humoral mediators to stimulate the regeneration process within the tendon. 6 This study compared the efficacy of autologous blood injection versus corticosteroid injection for the treatment of lateral epicondylitis.
MATERIALS AND METHODS
This study was approved by the local ethics committee and carried out in accordance with the Declaration of Helsinki. Informed consent was obtained from each patient. The diagnosis of lateral epicondylitis was made based on presentation of pain in the lateral epicondyle exacerbated by physical activities, tenderness over the origin of extensor carpi radialis brevis 5 to 10 mm distal to the lateral epicondyle, and finger palpation and pain around the extensor origin during forced dorsiflexion of the wrist and middle finger.
Between May 2012 and May 2013, 21 men and 59 women (mean age, 45.2 years) presenting with lateral epicondylitis were randomised to receive either autologous blood injection (2 ml of autologous venous blood collected from the antecubital fossa of the ipsilateral side mixed with 1 ml of 2% prilocaine hydrochloride) or corticosteroid injection (1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine hydrochloride) given by a single physician. Patients were instructed to abstain from heavy work; non-steroidal anti-inflammatory drugs or physiotherapy was not prescribed.
Patients with a history of recent trauma, congenital or neuromuscular disease, upper limb surgery, rheumatic disease, cervical disc pathology, carpal tunnel syndrome, abnormality of the upper limb, systemic corticosteroid treatment, local injection treatment, or an allergic reaction to local anaesthetics or corticosteroids were excluded.
Patients' occupations were categorised according to physical demand as sedentary, light, medium, heavy, and very heavy. 7 Patients were assessed before (day 0) and after (days 15, 30, and 90) treatment for elbow pain (using a visual analogue scale [VAS]), function (using the Turkish version of the patient-rated tennis elbow evaluation [PRTEE] questionnaire 8 ), and grip strength (using a hydraulic hand dynamometer according to the American Society of Hand Therapists guidelines 9 ). The PRTEE consists of 15 questions in 3 subscales: pain (n=5), specific activities (n=6), and daily activities (n=4); the total score ranges from 0 (best) to 100 (worst). 10 Patients were followed up at 6 months by telephone to assess elbow pain using the VAS.
Continuous and categorical variables were All patients completed the 6-month follow-up. The baseline characteristics of both groups were similar (Table 1) . No complications (infection, skin atrophy, neurovascular damage, or tendon rupture) were noted. 10 patients reported increased pain for up to 2 days after autologous blood injection.
In both groups, the VAS score for elbow pain, PRTEE score, and grip strength improved significantly after treatment (p=0.0001), but the pattern of improvement differed (Table 2) . Compared with autologous blood injection, corticosteroid injection improved all 3 scores at a faster rate over the first 15 days (p=0.0001), and then started to decline slightly until day 90. After autologous blood injection, all 3 scores improved steadily and were eventually better (p=0.0001). If a 37% decrease in PRTEE is defined as complete recovery (or minimum clinically important difference), 11 38 (95%) of patients with autologous blood injection and 25 (62.5%) of patients with corticosteroid injection achieved complete recovery (p=0.0001).
discussion
Autologous blood injection was more effective than corticosteroid injection in terms of pain control, functional recovery, and grip strength. The complete recovery rate at 3 months was 95% after autologous blood injection and 62.5% after corticosteroid injection. Corticosteroid injection enabled a rapid but temporary improvement in the first month. 12 Autologous blood injection stimulates the inflammatory cascade within the degenerated tendon by providing cellular and humoral mediators for regeneration. 6 Ultrasonographic evidence of tendon reparation, such as decreased interstitial clefts and anechoic foci within the tendon, and decreased pathological vascularity have been reported. 13 The recovery rates after autologous blood injection have been reported to be 79% after a mean of 9.5 months, 6 94.2% after 6 months, 13 and 58% after 8 months.
14 Poorer outcomes may reflect the chronic refractory nature of the condition and longer duration of symptoms.
Lateral epicondylitis was initially assumed to be an inflammatory process, and thus corticosteroid injection was used. 15 However, histological studies have demonstrated non-inflammatory angiofibroblastic tendinosis, neovascularisation, and mucoid degeneration in lateral epicondylitis specimens. [16] [17] [18] The presence of substance P, calcitonin gene-related peptide, and Neurokinin 1-receptors in tendon insertions may be related to pain. 17, 18 Reduction of these neuropeptides by corticosteroid injection can reduce the pain dramatically. 19 However, the underlying pathology remains and the recurrence rate is high. Corticosteroid injection has superior short-term effects but no intermediate or long-term effects. 20, 21 In a review of 12 studies for treatment of lateral epicondylitis, the use of autologous blood, corticosteroid, platelet-rich plasma, placebo, or extracorporeal shock wave therapy were compared (Table 3) . 6, 13, 14, [22] [23] [24] [25] [26] [27] [28] [29] [30] Autologous blood injection was more effective in the long term than corticosteroid injection in improving pain and tenderness, although corticosteroid injection enabled faster pain relief. Extracorporeal shock wave therapy was also more effective than corticosteroid injection in the long term. 26 One study reported no significant difference between autologous blood injection, corticosteroid injection, and placebo. 25 Lateral epicondylitis is a self-limiting disease and relief of symptoms is related to duration of time. 25 Platelet-rich plasma has higher levels of growth factors for stimulation of regeneration, and yields similar results to autologous blood in terms of pain reduction and functional improvement at 6 months. 27, 28 However, the need for surgical intervention was higher after platelet-rich plasma injection than autologous blood injection (20% vs. 10%). 28 In addition, preparation and application of platelet-rich plasma requires specialised equipment, which is expensive and time-consuming.
One limitation of this study was that the followup period was relatively short. Both the physician and the patients were not blinded to the treatment modality and this may have caused bias. A single physician performed all injections and evaluations and this may also have been a source of bias.
conclusion
Autologous blood injection was more effective over the follow-up period than corticosteroid injection in improving pain, function, and grip strength. It is recommended as a first-line injection treatment because it is simple, cheap, and effective.
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